S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

SCYNEXIS (SCYX) Stock Forecast, Price & News

+0.02 (+0.95%)
(As of 05/20/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
119,454 shs
Average Volume
440,394 shs
Market Capitalization
$69.07 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SCYX News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter.



SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.


Earnings Outlook For SCYNEXIS - Benzinga
SCYNEXIS (SCYX) to Release Earnings on Thursday
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$13.16 million
Book Value
$1.19 per share


Net Income
$-32.87 million
Pretax Margin




Free Float
Market Cap
$69.07 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.26 out of 5 stars

Medical Sector

314th out of 1,416 stocks

Pharmaceutical Preparations Industry

119th out of 677 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions

Is SCYNEXIS a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SCYNEXIS stock.
View analyst ratings for SCYNEXIS
or view top-rated stocks.

When is SCYNEXIS's next earnings date?

SCYNEXIS is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for SCYNEXIS

How were SCYNEXIS's earnings last quarter?

SCYNEXIS, Inc. (NASDAQ:SCYX) issued its quarterly earnings results on Thursday, May, 12th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.74) by $0.56. During the same quarter last year, the firm earned ($0.23) earnings per share.
View SCYNEXIS's earnings history

When did SCYNEXIS's stock split? How did SCYNEXIS's stock split work?

SCYNEXIS shares reverse split on Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 16th 2020. An investor that had 100 shares of SCYNEXIS stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for SCYX?

3 Wall Street analysts have issued 1-year price targets for SCYNEXIS's shares. Their forecasts range from $8.00 to $35.00. On average, they expect SCYNEXIS's stock price to reach $21.50 in the next year. This suggests a possible upside of 914.2% from the stock's current price.
View analysts' price targets for SCYNEXIS
or view top-rated stocks among Wall Street analysts.

Who are SCYNEXIS's key executives?
SCYNEXIS's management team includes the following people:
  • Dr. Marco Taglietti M.D., CEO, Pres & Director (Age 62, Pay $991.27k)
  • Mr. David Gonzalez Angulo, Chief Medical Officer (Age 57, Pay $709.66k)
  • Mr. Lawrence R. Hoffman CPA, Esq., Interim CFO & Principal Accounting Officer (Age 67)
  • Mr. Scott Sukenick J.D., Gen. Counsel & Corp. Sec. (Age 44)
  • Debbie Etchison, Exec. Director of Communications
  • Dr. Rajeshwar Motheram, Sr. VP of Pharmaceutical Devel. & Supply Chain
  • Ms. Christine R. Coyne M.B.A., Chief Commercial Officer
What other stocks do shareholders of SCYNEXIS own?
What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

Who are SCYNEXIS's major shareholders?

SCYNEXIS's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include AIGH Capital Management LLC (7.73%), Worth Venture Partners LLC (1.72%), Decheng Capital Management III Cayman LLC (1.92%), D.A. Davidson & CO. (1.02%), State Street Corp (0.27%) and Chicago Partners Investment Group LLC (0.15%). Company insiders that own SCYNEXIS stock include Brian Philippe Tinmouth, Eric Francois, Marco Taglietti, Perceptive Advisors Llc and Scott Sukenick.
View institutional ownership trends for SCYNEXIS

Which institutional investors are selling SCYNEXIS stock?

SCYX stock was sold by a variety of institutional investors in the last quarter, including Simplex Trading LLC.
View insider buying and selling activity for SCYNEXIS
or view top insider-selling stocks.

Which institutional investors are buying SCYNEXIS stock?

SCYX stock was bought by a variety of institutional investors in the last quarter, including Decheng Capital Management III Cayman LLC, AIGH Capital Management LLC, Worth Venture Partners LLC, Chicago Partners Investment Group LLC, State Street Corp, Citigroup Inc., D.A. Davidson & CO., and Group One Trading L.P.. Company insiders that have bought SCYNEXIS stock in the last two years include Brian Philippe Tinmouth, Eric Francois, Marco Taglietti, and Scott Sukenick.
View insider buying and selling activity for SCYNEXIS
or or view top insider-buying stocks.

How do I buy shares of SCYNEXIS?

Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SCYNEXIS's stock price today?

One share of SCYX stock can currently be purchased for approximately $2.12.

How much money does SCYNEXIS make?

SCYNEXIS has a market capitalization of $69.07 million and generates $13.16 million in revenue each year. The company earns $-32.87 million in net income (profit) each year or ($1.51) on an earnings per share basis.

How many employees does SCYNEXIS have?

SCYNEXIS employs 38 workers across the globe.

What is SCYNEXIS's official website?

The official website for SCYNEXIS is www.scynexis.com.

How can I contact SCYNEXIS?

SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company can be reached via phone at (201) 884-5485, via email at [email protected], or via fax at 201-884-5490.

This page was last updated on 5/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.